SLEEPING PILLS - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Sleeping Pills in US$ Million. Annual estimates and forecasts are provided for the period of 2007 through 2015. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 34 companies including many key and niche players such as -

Actelion Pharmaceuticals Ltd.
Abbott India Limited
Apotex Inc.
Aurobindo Pharma Limited
Caraco Pharmaceutical Laboratories, Ltd.
Dr. Reddy's Laboratories Limited


Click here to request a full list of companies covered in the report...

Code: MCP-6368
Price: $3950
Companies: 34
Pages: 339
Date: August 2010
Market Data Tables: 146

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
   Safety Concerns and Generics Characterize the Market.....II-1
“Perfect” Treatment Option Continues to Evade Insomnia Therapeutics Arena.....II-1
1$100
   A Market Characterized by Weak Pipeline.....II-2
Market Outlook.....II-2
Sleep Disorders – Not Confined to Elderly Alone.....II-2
US Leads the Global Market for Sleeping Pills.....II-2
1$100
   Table 1: US Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart).....II-3
Studies Cast Doubt On the Efficacy of Sleeping Pills.....II-3
1$300
   Market Categorization.....II-4
Table 2: Select Benzodiazepines and Non-Benzodiazepines Worldwide.....II-4
1$300
   Benzodiazepines Loose Sheen Due to Associated Side Effects.....II-5
‘Z’ Drugs Outshine Benzodiazepines with Lesser Adverse Effects...II-5
Table 3: Sales of Select Leading Sleeping Pills Worldwide.....II-5
1$300
   Melatonin Receptor Agonist Hypnotic.....II-6
Rozerem – The Only Drug without the Risk of Dependency.....II-6
1$100
   Zolpidem (Sanofi-Aventis/Various).....II-7
Ambien CR (Sanofi-Aventis).....II-7
Lunesta (Sepracor).....II-7
1$100
   Intermezzo (Transcept).....II-8
Sonata (King Pharmaceuticals).....II-8
Imovane (Sanofi-Aventis).....II-8
1$100
   Sleep Disorder Pipeline Analysis.....II-91$100
   Insomnia – A Review.....II-10
Impact on Day-to-day Life.....II-10
Insomnia: An Under-Diagnosed Disease.....II-10
1$100
   Middle-Of-The-Night Insomnia.....II-11
What are Sleeping Pills?.....II-11
When it Should be Taken?.....II-11
Side Effects – A Key Concern.....II-11
1$100
   Natural Treatment of Insomnia.....II-12
Eye Cells – A New Potential Target for Sleeping Pills.....II-12
1$100
   Regional Market Perspective.....II-13
6a. THE UNITED STATES.....II-13
Economic Woes Drive Usage of Sleeping Pills.....II-13
Table 4: Sleeping Pills Prescription Volume in the US: 2006-2008 (includes corresponding Graph/Chart).....II-13
1$300
   Table 5: Sleeping Pills Prescription Volume in the US by Drug: 2006-2008 (In Million) (includes corresponding Graph/Chart).....II-14
Dangerous Signs for Americans.....II-14
OTC Sleeping Aids Market Review.....II-14
1$300
   Table 6: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Value Sales for Simply Sleep, Unisom SleepGels, Unisom SleepTabs, Sleep MD, Sominex, Midnite, Breathe Right, Sleepinal, Private Label Brands and Others (includes corresponding Graph/Chart).....II-15

Table 7: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom SleepGels, Sominex, Unisom SleepTabs, Sleep MD, Midnite, Sleepinal, Breathe Right, Private Labels and Others (includes corresponding Graph/Chart).....II-15
1$300
   Table 8: Leading OTC Sleeping Aid Liquid Drugs in the US Drug Stores (2007): Percentage Breakdown of Value Sales for Breathe Right, Snorestop, Bach Rescue Sleep, Nutramist Sleep Now, Nutranetics Liquid Sleep and Others (includes corresponding Graph/Chart).....II-16

Table 9: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Value Sales for Simply Sleep, Unisom Sleepgels, Sleep MD, Unisom, Sominex and Others (includes corresponding Graph/Chart).....II-16

Table 10: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom Sleepgels, Sominex, Unisom, Sleep MD and Others (includes corresponding Graph/Chart).....II-16
1$300
   6b. EUROPE.....II-17
Europe: A Major Market for Sleeping Pills.....II-17
Table 11: European Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart).....II-17
1$300
   Table 12: Sleeping Disorders in Europe (2008): Prevalence Rate by Age Group for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart).....II-18

Table 13: Sleeping Disorders in Europe (2008): Prevalence Rate by Gender for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart).....II-18
1$300
   6c. JAPAN.....II-19
Illegal Sales of Sleeping Pills Rampant in Japan.....II-19
1$100
   6d. TAIWAN.....II-20
Sleeping Pills Sales Continue to Soar.....II-20
1$100
   Somaxon Pharma Receives US FDA Approval for Silenor.....II-21
Transcept Pharmaceuticals Merges with Novacea.....II-21
Sepracor Files Lawsuits Against ANDA Filers for Eszopiclone.....II-21
1$100
   Dainippon Sumitomo Takes Over Sepracor.....II-22
FDA Puts Two Pediatric Studies of Lunesta on Hold.....II-22
Transcept Pharmaceuticals Signs Deal with Purdue Pharmaceutical Products.....II-22
Sepracor Receives Approval for Lunesta Oral Tablet.....II-22
FDA Approves Mylan’s ANDA for Zaleplon Capsules.....II-22
1$100
   GlaxoSmithKline Signs Agreement with Actelion.....II-23
Lundbeck Launches Circadin® in Germany for Insomnia.....II-23
Lundbeck Launches Circadin in the UK.....II-23
Transcept Completes Phase III Study of Intermezzo, Files NDA.....II-23
1$100
   Evotec Scouts for Partners to Develop EVT 201.....II-24
Aurobindo Pharma Receives FDA Approval for Zaleplon.....II-24
Australia’s TGA Orders Boxed Warnings for Stilnox.....II-24
Sepracor Obtains Positive Opinion for Approval of Lunivia from CHMP.....II-24
1$100
   Caraco Obtains FDA Approval for Generic Zolpidem.....II-25
FDA Approves ANDA of Dr. Reddy's Laboratories for Zolpidem Tartrate.....II-25
Ranbaxy Obtains FDA Clearance to Market Generic Ambien®.....II-25
Neurocrine Obtains Second Approvable Letter from FDA for Indiplon Capsules.....II-25
1$100
   Roxane Launches Zolpidem Tartrate Tablets.....II-261$100
   Actelion Pharmaceuticals Ltd. (Switzerland).....II-27
Abbott India Limited (India).....II-27
Apotex Inc. (Canada).....II-27
Aurobindo Pharma Limited (India).....II-27
1$100
   Caraco Pharmaceutical Laboratories, Ltd. (US).....II-28
Dr. Reddy’s Laboratories Limited (India).....II-28
H. Lundbeck A/S (Denmark).....II-28
King Pharmaceuticals, Inc. (US).....II-28
1$100
   Neurocrine Biosciences (US).....II-29
Ranbaxy Laboratories Limited (India).....II-29
Roxane Laboratories, Inc. (US).....II-29
Sepracor, Inc. (USA).....II-29
1$100
   Sanofi-aventis (France).....II-301$100
   Somaxon Pharmaceuticals, Inc. (US).....II-31
Synthon BV (The Netherlands).....II-31
Takeda Pharmaceutical Company Limited (Japan).....II-31
Transcept Pharmaceuticals, Inc. (US).....II-31
1$100
   Table 14: World Recent Past, Current and Future Analysis for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-321$300
   Table 15: World Historic Review for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-331$300
   Table 16: World 13-Year Perspective for Sleeping Pills by Geographic Region - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....II-341$300
  
Total Companies Profiled: 34 (including Divisions/Subsidiaries - 39)

Region/Country Players

The United States 22 Canada 1 Japan 3 Europe 9 France 1 Germany 2 The United Kingdom 1 Rest of Europe 5 Asia-Pacific (Excluding Japan) 4
Click here to request a full table of contents and more details on this project.